<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-26163" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Omega-3 Fatty Acids</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Krupa</surname>
            <given-names>Kristina N.</given-names>
          </name>
          <aff>Department of Obstetrics and Gynecology, Medical City Arlington, Arlington, TX USA</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Fritz</surname>
            <given-names>Kristina</given-names>
          </name>
          <aff>Nova Southeastern University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Parmar</surname>
            <given-names>Mayur</given-names>
          </name>
          <aff>Nova Southeastern University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Kristina Krupa declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Kristina Fritz declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mayur Parmar declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>28</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-26163.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Omega-3 (&#x003c9;-3) fatty acids, renowned for their multiple health benefits, are pivotal in managing hyperlipidemia by modulating lipid profiles. This comprehensive activity explores the indications for omega-3 fatty acids, elucidating their multifunctional actions in various cardiovascular conditions. In addition to their well-established lipid-lowering effects, these acids exhibit anti-inflammatory, antiarrhythmic, and vasodilatory properties, influencing atherosclerotic processes and cardiac rhythm regulation.&#x000a0;Additionally, the activity will discuss&#x000a0;contraindications, emphasizing safe utilization.</p>
        <p>The core of this activity focuses on the mechanisms of action underlying the diverse effects of omega-3 fatty acids, in addition to shedding light on their pharmacokinetics, pharmacodynamics, dosing considerations, and potential interactions. The program covers off-label uses, emphasizing their roles beyond lipid management, including reducing triglycerides, addressing inflammation, and mitigating cardiovascular risks. This activity facilitates understanding their adverse event profile and monitoring requirements,&#x000a0;allowing healthcare team members to use omega-3 fatty acids as a therapy component properly. This ensures patient safety and optimizes treatment efficacy in hyperlipidemia and&#x000a0;associated conditions.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the appropriate omega-3 fatty acid supplementation indications in patients with hyperlipidemia or cardiovascular risk factors.</p></list-item><list-item><p>Differentiate between various sources and formulations of omega-3 fatty acids, highlighting their respective compositions, dosages, and potential benefits for specific patient populations.</p></list-item><list-item><p>Implement omega-3 fatty acids into a comprehensive treatment plan, emphasizing the importance of dietary counseling and lifestyle modifications.</p></list-item><list-item><p>Select a therapy approach&#x000a0;with other healthcare professionals to ensure coordinated care.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=26163&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=26163">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-26163.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Omega-3 fatty acids are polyunsaturated fatty acids (PUFAs) with at least one double bond between the third and fourth omega-end carbon. Currently, the&#x000a0;3 most clinically relevant omega-3 polyunsaturated fatty acids (PUFAs) are &#x003b1;-linolenic acid (ALA), eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA). Oils containing these fatty acids originate in plant sources and can be found in fish, fish products, seeds, nuts, green leafy vegetables, and beans.<xref ref-type="bibr" rid="article-26163.r1">[1]</xref><xref ref-type="bibr" rid="article-26163.r2">[2]</xref></p>
        <p>The FDA has approved 2 prescription omega-3 fatty acids products: icosapent ethyl and omega-3-acid ethyl esters. Omega-3-carboxylic acids&#x000a0;and omega-3-acid ethyl esters A are prescription omega-3 fatty acids formulations that have since been discontinued. Omega-3-acid ethyl esters, omega-3-carboxylic acids, and omega-3-acid ethyl esters A contain both EPA and DHA, whereas icosapent ethyl contains ethyl esters of EPA only.<xref ref-type="bibr" rid="article-26163.r3">[3]</xref>&#x000a0;Iosapent ethyl and omega-3-acid ethyl esters are approved for adults with very high triglycerides (&#x02265;500 mg/dL) as an adjunct to diet to decrease triglyceride levels and reduce cardiovascular events.<xref ref-type="bibr" rid="article-26163.r4">[4]</xref><xref ref-type="bibr" rid="article-26163.r5">[5]</xref><xref ref-type="bibr" rid="article-26163.r3">[3]</xref><xref ref-type="bibr" rid="article-26163.r6">[6]</xref>&#x000a0;</p>
        <p>These prescription omega-3 fatty acids products have also been recommended in adjunctive therapy in combination with statins to enhance the reduction of the total cholesterol/high-density lipoprotein cholesterol compared to statin alone.<xref ref-type="bibr" rid="article-26163.r7">[7]</xref><xref ref-type="bibr" rid="article-26163.r8">[8]</xref><xref ref-type="bibr" rid="article-26163.r9">[9]</xref>&#x000a0;However, some studies have urged physicians to proceed with caution when prescribing a statin/DHA omega-3 fatty acid combination due to the possibility of increased low-density lipoprotein (LDL) cholesterol.<xref ref-type="bibr" rid="article-26163.r7">[7]</xref><xref ref-type="bibr" rid="article-26163.r10">[10]</xref><xref ref-type="bibr" rid="article-26163.r11">[11]</xref>&#x000a0;DHA containing omega-3 fatty acids can be switched to EPA-only icosapent ethyl, which is not associated with increased LDL.<xref ref-type="bibr" rid="article-26163.r10">[10]</xref><xref ref-type="bibr" rid="article-26163.r11">[11]</xref></p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Severe hypertriglyceridemia in adults</p>
          </list-item>
        </list>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <p>It is important to note that while these prescription omega-3 fatty acids products are the only FDA-approved products for the treatment of hypertriglyceridemia, ongoing research is currently investigating the significance of omega-3 fatty acids and their promising role in the treatment of conditions and ailments listed below:</p>
        <list list-type="bullet">
          <list-item>
            <p>Cardiovascular disease&#x000a0;<xref ref-type="bibr" rid="article-26163.r1">[1]</xref><xref ref-type="bibr" rid="article-26163.r12">[12]</xref><xref ref-type="bibr" rid="article-26163.r13">[13]</xref><xref ref-type="bibr" rid="article-26163.r14">[14]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Hypertriglyceridemia (200&#x000a0;to 499 mg/dL)&#x000a0;<xref ref-type="bibr" rid="article-26163.r4">[4]</xref></p>
          </list-item>
          <list-item>
            <p>Type 2 diabetes&#x000a0;<xref ref-type="bibr" rid="article-26163.r1">[1]</xref></p>
          </list-item>
          <list-item>
            <p>Cancer&#x000a0;<xref ref-type="bibr" rid="article-26163.r1">[1]</xref><xref ref-type="bibr" rid="article-26163.r15">[15]</xref><xref ref-type="bibr" rid="article-26163.r16">[16]</xref><xref ref-type="bibr" rid="article-26163.r14">[14]</xref></p>
          </list-item>
          <list-item>
            <p>Alzheimer disease and dementia&#x000a0;<xref ref-type="bibr" rid="article-26163.r1">[1]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Depression&#x000a0;<xref ref-type="bibr" rid="article-26163.r1">[1]</xref></p>
          </list-item>
          <list-item>
            <p>Visual and neurological/brain development&#x000a0;<xref ref-type="bibr" rid="article-26163.r1">[1]</xref></p>
          </list-item>
          <list-item>
            <p>Maternal health during pregnancy and child health&#x000a0;<xref ref-type="bibr" rid="article-26163.r1">[1]</xref></p>
          </list-item>
          <list-item>
            <p>Conditions benefiting from prebiotics&#x000a0;<xref ref-type="bibr" rid="article-26163.r17">[17]</xref></p>
          </list-item>
          <list-item>
            <p>Heart failure&#x000a0;<xref ref-type="bibr" rid="article-26163.r18">[18]</xref><xref ref-type="bibr" rid="article-26163.r13">[13]</xref></p>
          </list-item>
          <list-item>
            <p>Intervertebral disc degeneration&#x000a0;<xref ref-type="bibr" rid="article-26163.r19">[19]</xref></p>
          </list-item>
          <list-item>
            <p>Attention deficit hyperactivity disorder&#x000a0;<xref ref-type="bibr" rid="article-26163.r20">[20]</xref><xref ref-type="bibr" rid="article-26163.r21">[21]</xref></p>
          </list-item>
          <list-item>
            <p>Maternal depression&#x000a0;<xref ref-type="bibr" rid="article-26163.r22">[22]</xref></p>
          </list-item>
          <list-item>
            <p>Menopausal night sweats&#x000a0;<xref ref-type="bibr" rid="article-26163.r23">[23]</xref></p>
          </list-item>
          <list-item>
            <p>Rheumatoid arthritis&#x000a0;<xref ref-type="bibr" rid="article-26163.r1">[1]</xref><xref ref-type="bibr" rid="article-26163.r14">[14]</xref></p>
          </list-item>
          <list-item>
            <p>Asthma&#x000a0;<xref ref-type="bibr" rid="article-26163.r24">[24]</xref><xref ref-type="bibr" rid="article-26163.r25">[25]</xref><xref ref-type="bibr" rid="article-26163.r14">[14]</xref></p>
          </list-item>
          <list-item>
            <p>Periodontal disease&#x000a0;<xref ref-type="bibr" rid="article-26163.r1">[1]</xref><xref ref-type="bibr" rid="article-26163.r26">[26]</xref></p>
          </list-item>
          <list-item>
            <p>Epilepsy&#x000a0;<xref ref-type="bibr" rid="article-26163.r27">[27]</xref><xref ref-type="bibr" rid="article-26163.r28">[28]</xref></p>
          </list-item>
          <list-item>
            <p>Diabetic retinopathy&#x000a0;<xref ref-type="bibr" rid="article-26163.r2">[2]</xref><xref ref-type="bibr" rid="article-26163.r29">[29]</xref></p>
          </list-item>
          <list-item>
            <p>Chemotherapy adjunct&#x000a0;<xref ref-type="bibr" rid="article-26163.r30">[30]</xref><xref ref-type="bibr" rid="article-26163.r1">[1]</xref><xref ref-type="bibr" rid="article-26163.r31">[31]</xref></p>
          </list-item>
          <list-item>
            <p>Premenstrual syndrome&#x000a0;<xref ref-type="bibr" rid="article-26163.r32">[32]</xref></p>
          </list-item>
          <list-item>
            <p>Non-alcoholic fatty liver disease&#x000a0;<xref ref-type="bibr" rid="article-26163.r33">[33]</xref></p>
          </list-item>
        </list>
        <p>Omega-3 intake or supplementation has&#x000a0;demonstrated benefits in treating the above conditions; controversy still exists&#x000a0;for many of the above uses. More research with well-conducted clinical trials must be completed before definitive conclusions can be made.</p>
      </sec>
      <sec id="article-26163.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>The mechanism of action of omega-3 fatty acids to lower triglycerides (FDA-approved use) is still not fully known. They are thought to lower triglycerides by suppressing lipogenic gene expression, increasing beta-oxidation of fatty acids, increasing the expression of lipoprotein-lipase (LPL), and influencing total body lipid accretion.<xref ref-type="bibr" rid="article-26163.r34">[34]</xref><xref ref-type="bibr" rid="article-26163.r35">[35]</xref><xref ref-type="bibr" rid="article-26163.r36">[36]</xref></p>
        <p>Omega-3 fatty acids suppress lipogenic gene expression by decreasing the expression of sterol regulatory element-binding protein 1c, inhibiting phosphatidic acid phosphatase, and acyl-CoA:1,2-diacylglycerol acyltransferase (NGAT). Sterol regulatory element-binding proteins (SREBPs) are membrane-bound enzymes that, when cleaved, travel to the nucleus to transcribe enzymes involved in cholesterol, LDL, and fatty acid synthesis. When a diet is high in omega-3 fatty acids, the SREBPs (particularly 1c) are not activated because of negative feedback inhibition and lowers SREBP synthesis and the cholesterol synthesizing enzymes that it regulates, FPP synthase (farnesyl diphosphate synthase) and HMG-CoA reductase (3-hydroxy-3-methylglutaryl-CoA reductase).<xref ref-type="bibr" rid="article-26163.r37">[37]</xref><xref ref-type="bibr" rid="article-26163.r38">[38]</xref></p>
        <p>Beta-oxidation is the biological pathway used in the body to break down fat and convert it into energy.<xref ref-type="bibr" rid="article-26163.r35">[35]</xref> Omega-3 fatty acids decrease the&#x000a0;level of triacylglycerides in the body by increasing the rate of beta-oxidation by acting specifically on carnitine acetyltransferase 1 (CAT1) and acetyl-CoA carboxylase.<xref ref-type="bibr" rid="article-26163.r34">[34]</xref><xref ref-type="bibr" rid="article-26163.r35">[35]</xref> Carnitine acetyltransferase modifies fatty acid substrates to enter the inner mitochondrial membrane via carnitine-acylcarnitine translocation. Later, they are converted to acyl-CoA, a precursor substrate to acetyl-CoA used to create ATP in various metabolic pathways.<xref ref-type="bibr" rid="article-26163.r35">[35]</xref> Additionally, EPA also indirectly increases beta-oxidation by slowing feedback inhibition.<xref ref-type="bibr" rid="article-26163.r35">[35]</xref> EPA inhibits acetyl-CoA carboxylase, which is the enzyme that catalyzes the synthesis of malonyl-CoA, a strong inhibitor of CAT1.<xref ref-type="bibr" rid="article-26163.r35">[35]</xref> By decreasing the amount of malonyl-CoA produced, CAT1 will have increased activity and use more triacylglycerides for beta-oxidation. Omega-3 fatty acids&#x000a0;have also been shown to decrease the sensitivity of CAT1 to malonyl-CoA.<xref ref-type="bibr" rid="article-26163.r35">[35]</xref></p>
        <p>Lipoprotein lipase (LPL) is an extracellular enzyme found on the endothelium of vascular tissue that functions to remove triacylglycerol components of chylomicrons, low-density lipoproteins (LDL), and very-low-density lipoproteins (VLDL) in the blood.<xref ref-type="bibr" rid="article-26163.r39">[39]</xref><xref ref-type="bibr" rid="article-26163.r40">[40]</xref><xref ref-type="bibr" rid="article-26163.r41">[41]</xref>&#x000a0;A diet high in omega-3 fatty acids has been shown to increase the expression of LPL and subsequent lipoprotein lipase protein on the endothelial lining and decrease the size of chylomicrons.<xref ref-type="bibr" rid="article-26163.r42">[42]</xref>&#x000a0;Increasing the amount of lipoprotein lipase and decreasing LDL, VLDL, and chylomicron size can lower triglycerides in patients with hypertriglyceridemia.</p>
        <p>Omega-3 fatty acids are also believed to reduce high triglycerides by influencing total body lipid accretion. Several studies have found that prolonged use of omega-3 fatty acids for&#x000a0;more than&#x000a0;6 weeks can increase the body's metabolic rate and decrease total body fat.<xref ref-type="bibr" rid="article-26163.r43">[43]</xref><xref ref-type="bibr" rid="article-26163.r35">[35]</xref><xref ref-type="bibr" rid="article-26163.r44">[44]</xref>&#x000a0;More specifically, study participants showed increased lean muscle mass, decreased fat mass, increased resting metabolic rate, increased energy expenditure during exercise, and increased fat oxidation during rest and exercise.<xref ref-type="bibr" rid="article-26163.r43">[43]</xref><xref ref-type="bibr" rid="article-26163.r35">[35]</xref><xref ref-type="bibr" rid="article-26163.r45">[45]</xref><xref ref-type="bibr" rid="article-26163.r44">[44]</xref>&#x000a0;This occurs due to omega-3 fatty acids' ability to act as a ligand for peroxisome proliferator-activated receptors (PPARs), whose transcription factor activity can change gene expression in energy homeostasis.<xref ref-type="bibr" rid="article-26163.r43">[43]</xref><xref ref-type="bibr" rid="article-26163.r46">[46]</xref>&#x000a0;PPARs regulate both fatty acid metabolism (beta-oxidation) and glucose metabolism and can change the basal metabolism of the cell.<xref ref-type="bibr" rid="article-26163.r47">[47]</xref> The increase in fat oxidation and energy needs by changes in body composition is thought to be another mechanism by which omega-3 fatty acids help lower the triglyceride levels in the blood.</p>
        <p>Additional mechanisms of action for omega-3 fatty acids explain the beneficial effects on the brain, brain development, cancer, diabetes, rheumatoid arthritis, irritable bowel disease, and the cardiovascular system outside triglyceride regulation. Most of these effects are attributed to omega-3 fatty acids' anti-inflammatory actions. Omega-3 fatty acids have been shown to modulate several inflammatory pathways.<xref ref-type="bibr" rid="article-26163.r18">[18]</xref><xref ref-type="bibr" rid="article-26163.r48">[48]</xref><xref ref-type="bibr" rid="article-26163.r15">[15]</xref><xref ref-type="bibr" rid="article-26163.r49">[49]</xref><xref ref-type="bibr" rid="article-26163.r50">[50]</xref>&#x000a0;These include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Inhibition of leukocyte chemotaxis</p>
          </list-item>
          <list-item>
            <p>Inhibitions of adhesion molecule expression (like leukocyte-endothelial adhesive interactions)</p>
          </list-item>
          <list-item>
            <p>Inhibition of cyclooxygenase (COX) activity and its subsequent eicosanoid production (eg, leukotrienes and prostaglandins from arachidonic acid)</p>
          </list-item>
          <list-item>
            <p>Inhibition of pro-inflammatory cytokines (eg, TNF-&#x003b1;, IL-1, IL-6)</p>
          </list-item>
          <list-item>
            <p>Increase production of inflammation-resolving resolvins, maresins, lipoxins, and protectins</p>
          </list-item>
          <list-item>
            <p>Inhibition of pro-inflammatory transcription nuclear factor kappa B (nuclear factor-kB) activation</p>
          </list-item>
          <list-item>
            <p>Activation of anti-inflammatory transcription factor NR1C3</p>
          </list-item>
          <list-item>
            <p>Activation of PPARs</p>
          </list-item>
          <list-item>
            <p>Activation of G protein-coupled receptor GPR120</p>
          </list-item>
          <list-item>
            <p>Altering phospholipid fatty acid composition</p>
          </list-item>
          <list-item>
            <p>Disrupting lipid rafts</p>
          </list-item>
        </list>
        <p>Although many cancers are&#x000a0;aided by omega-3 fatty acids' anti-inflammatory effect and the tumor growth of non-small-cell lung cancer is&#x000a0;reduced by inhibiting acetyl-CoA carboxylase (decreasing fatty acid production), other antineoplastic mechanisms of omega-3 fatty acids can be beneficial for other cancers, such as breast cancer, colorectal cancer, leukemia, gastric cancer, pancreatic cancer, esophageal cancer, prostate cancer, head and neck cancer, as well as lung cancer.<xref ref-type="bibr" rid="article-26163.r51">[51]</xref><xref ref-type="bibr" rid="article-26163.r15">[15]</xref>&#x000a0;Omega-3 fatty acids activate AMPK/SIRT, which is involved in cell maintenance and repair, producing an antineoplastic effect useful in cancer treatment.<xref ref-type="bibr" rid="article-26163.r50">[50]</xref><xref ref-type="bibr" rid="article-26163.r15">[15]</xref></p>
        <p>Omega-3 fatty acids can stabilize and protect certain tissues with high-fat content, like neural and retinal tissue. Alzheimer disease, dementia, and cognitive function are improved by omega-3 fatty acids' ability to maintain cell membranes of neural tissues because DHA is an essential component of the brain's phospholipid membranes.<xref ref-type="bibr" rid="article-26163.r52">[52]</xref><xref ref-type="bibr" rid="article-26163.r53">[53]</xref><xref ref-type="bibr" rid="article-26163.r54">[54]</xref> Additionally, macular degeneration can be helped by supplementing DHA for structural support and EPA-based eicosanoids for neovascular and cell survival because DHA and EPA are also integral components of retinal cell membranes.<xref ref-type="bibr" rid="article-26163.r55">[55]</xref></p>
        <p>Omega-3 fatty acids have some cardioprotective effects that help protect against heart failure in patients with congestive heart failure (CHF). Omega-3 fatty acids, specifically DHA, decrease mitochondrial oxygen consumption without reducing ventricle power generation by altering the mitochondrial membrane phospholipid composition, protecting the heart from tiring.<xref ref-type="bibr" rid="article-26163.r18">[18]</xref>&#x000a0;EPA inhibits the apoptotic activity stimulated by saturated fatty acid cardiac lipotoxicity, protecting the heart from injury.<xref ref-type="bibr" rid="article-26163.r18">[18]</xref>&#x000a0;Omega-3 fatty acids can protect from arrhythmia by inhibiting inward sodium current in a dose-dependent manner, suppressing intracellular calcium (Ca<sup>2+</sup>) waves, and helping strengthen autonomic tone.<xref ref-type="bibr" rid="article-26163.r56">[56]</xref>&#x000a0;Omega-3 fatty acids can also vasodilate and decrease blood pressure or afterload to help the heart pump more easily because they stimulate nitrous oxide (NO) release from vascular endothelial tissue.<xref ref-type="bibr" rid="article-26163.r18">[18]</xref>&#x000a0;Omega-3 fatty acids also protect the heart through their antithrombotic and antiatherosclerotic abilities. Omega-3 fatty acids have been shown to suppress platelet-derived thromboxane A2 (TxA2) synthesis, constrict blood vessels, aid in platelet aggregation, and reduce the production of matrix metalloproteinases released by macrophages when there is endothelial injury.<xref ref-type="bibr" rid="article-26163.r18">[18]</xref><xref ref-type="bibr" rid="article-26163.r57">[57]</xref></p>
        <p>It should be noted that numerous studies continue to determine the exact mechanisms by which omega-3 fatty acids have a pharmacological effect. Many studies with conflicting data challenge&#x000a0;the current understanding of how omega-3 fatty acids can help other conditions beyond hypertriglyceridemia.</p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold>&#x000a0;Digestion of omega-3 fatty acids begins in the stomach with gastric lipases that break down triacylglycerols into diacylglycerol and fatty acids.<xref ref-type="bibr" rid="article-26163.r1">[1]</xref>&#x000a0;Once broken down, they form fat globules broken down by pancreatic lipases and bile salts in the small intestines. The ethyl esters (icosapent ethyl, omega-3-acid ethyl esters, and omega-3-acid ethyl esters A) are principally broken down by pancreatic carboxylic acid ester lipase in the small intestine to form FFA-EPA and FFA-DHA.<xref ref-type="bibr" rid="article-26163.r1">[1]</xref>&#x000a0;Monoacylglycerols and the free fatty acids then passively diffuse into enterocytes as micelles.<xref ref-type="bibr" rid="article-26163.r1">[1]</xref>&#x000a0;Various fatty acid transport proteins in the enterocyte membrane can also transport fatty acids into enterocytes.<xref ref-type="bibr" rid="article-26163.r58">[58]</xref>&#x000a0;Once within the enterocyte, the fatty acids are re-performed into triacylglycerols in the endoplasmic reticulum that bind to apolipoproteins to form chylomicrons.<xref ref-type="bibr" rid="article-26163.r1">[1]</xref><xref ref-type="bibr" rid="article-26163.r58">[58]</xref>&#x000a0;Chylomicrons are exocytosed into the lymphatic system and ultimately enter circulation at the thoracic duct to reach target tissues.<xref ref-type="bibr" rid="article-26163.r1">[1]</xref><xref ref-type="bibr" rid="article-26163.r58">[58]</xref></p>
        <p>During&#x000a0;digestion, the ethyl esters are principally broken down by pancreatic carboxylic acid ester lipase, an enzyme with activity enhanced by high-fat meals.<xref ref-type="bibr" rid="article-26163.r1">[1]</xref>&#x000a0;Moreover, the fat content of a meal can affect the absorption of ethyl esters.<xref ref-type="bibr" rid="article-26163.r1">[1]</xref>&#x000a0;Subsequently, absorption of the ethyl esters and icosapent ethyl (EPA formulation only) is decreased when fasting, so it is recommended they are consumed with food.<xref ref-type="bibr" rid="article-26163.r4">[4]</xref>&#x000a0;EPA is thought not to absorb as well as DHA and is metabolized faster; there is a higher ratio of DHA to EPA within the serum plasma.<xref ref-type="bibr" rid="article-26163.r58">[58]</xref></p>
        <p><bold>Distribution:&#x000a0;</bold>EPA's volume of distribution is approximately 80L. The bioavailability of omega-3 fatty acids will be affected by the form they are found in, which can include triacylglycerols, free fatty acids, phospholipids, and ethyl esters.<xref ref-type="bibr" rid="article-26163.r1">[1]</xref>&#x000a0;The suggested bioavailability based on form (lipid structure) from highest to lowest is as follows: phospholipids, re-esterified triacylglycerols, triacylglycerols, free fatty acids, and ethyl esters.<xref ref-type="bibr" rid="article-26163.r59">[59]</xref>&#x000a0;However, the order is based on lipid structure only and does not reflect other factors that affect the bioavailability of omega-3 fatty acids, such as the fat content of a meal.<xref ref-type="bibr" rid="article-26163.r59">[59]</xref></p>
        <p>In addition to the form of the omega-3 fatty acid, the chemical positioning may also affect bioavailability. Research suggests&#x000a0;that omega-3 fatty acid content is greater in fish oil due to the acid typically being in the sn-2 position versus&#x000a0;the sn-1 and sn-3 positions found in marine mammal oils.<xref ref-type="bibr" rid="article-26163.r59">[59]</xref><xref ref-type="bibr" rid="article-26163.r1">[1]</xref>&#x000a0;Conversely, other sources state that omega-3 fatty acids bioavailability is increased in the sn-1 and sn-3 position due to increased accessibility for lipase hydrolysis, so controversy remains regarding how the position affects the bioavailability of the omega-3 fatty acids.<xref ref-type="bibr" rid="article-26163.r59">[59]</xref><xref ref-type="bibr" rid="article-26163.r58">[58]</xref>&#x000a0;Bioavailability also varies depending on the dietary source. For example, krill oil is known to have high bioavailability compared to other marine sources.<xref ref-type="bibr" rid="article-26163.r59">[59]</xref><xref ref-type="bibr" rid="article-26163.r58">[58]</xref>&#x000a0;Bioavailability of EPA only and both EPA/DHA formulations did not differ based on age or ethnicity; the combination formulation bioavailability differed based on gender. Women seem to have higher EPA serum levels than males in the mixed EPA/DHA formulations. However, research on the availability of EPA and DHA in over-the-counter supplements has indicated that age can play a factor in their levels within the plasma.<xref ref-type="bibr" rid="article-26163.r58">[58]</xref>&#x000a0;Research has also&#x000a0;determined that serum EPA increases dose-dependent when administered with ethyl esters, but serum DHA does not.<xref ref-type="bibr" rid="article-26163.r6">[6]</xref></p>
        <p><bold>Metabolism:</bold>&#x000a0;Omega-3 fatty acids undergo metabolism and oxidation in the liver, leading to the synthesis of VLDL to transport fatty acids in the plasma to various tissues. Omega-3 fatty acids-generated lipid signaling molecules are catalyzed by cyclooxygenase and lipooxygenase enzymes.&#x000a0;While most DHA and EPA metabolism occurs via beta-oxidation in the liver (as discussed above), cytochrome P450 (CYP)-mediated metabolism is a minor pathway in the breakdown of DHA and EPA.<xref ref-type="bibr" rid="article-26163.r60">[60]</xref></p>
        <p><bold>Elimination:&#x000a0;</bold>The route of elimination of&#x000a0;omega-3 fatty acids is unknown.&#x000a0;Compartmental studies have shown that approximate half-life values of ALA, DHA, and EPA are 1 hour, 20 hours, and 39 to 67 hours, respectively.<xref ref-type="bibr" rid="article-26163.r61">[61]</xref><xref ref-type="bibr" rid="article-26163.r62">[62]</xref>&#x000a0;With repeated administration, the half-life of EPA is 37 hours, and DHA has a half-life of 48 hours.<xref ref-type="bibr" rid="article-26163.r59">[59]</xref>&#x000a0;Not all the prescription omega-3 fatty acid product half-lives have been established. The maximum plasma EPA and DHA&#x000a0;levels can be determined within&#x000a0;5 to&#x000a0;9 hours post-administration.<xref ref-type="bibr" rid="article-26163.r59">[59]</xref>&#x000a0;However, persistent EPA and DHA serum levels will not be apparent until&#x000a0;2 weeks of daily supplementation.<xref ref-type="bibr" rid="article-26163.r59">[59]</xref></p>
      </sec>
      <sec id="article-26163.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Humans do not possess the enzymes required to synthesize omega-3 fatty acids; therefore, they are considered essential fatty acids because they must be obtained from the diet. Omega-3&#x000a0;fatty acids are consumed in&#x000a0;the human diet primarily as fish and plant sources but can also be consumed via prescription omega-3 fatty acid products.<xref ref-type="bibr" rid="article-26163.r59">[59]</xref>&#x000a0;Alpha-linoleic acid (ALA) is a common omega-3 fatty acid found in seeds and nuts and can be converted to DHA and EPA inside the body. However, research has found the conversion of DHA from ALA is particularly low, suggesting the importance of direct dietary intake of DHA.<xref ref-type="bibr" rid="article-26163.r1">[1]</xref><xref ref-type="bibr" rid="article-26163.r63">[63]</xref>&#x000a0;Omega-3 fatty acids may be present in several forms, such as triacylglycerols, free fatty acids (FFA), phospholipids, and ethyl esters.<xref ref-type="bibr" rid="article-26163.r1">[1]</xref>&#x000a0;Icosapent ethyl, omega-3-acid ethyl esters, and omega-3-acid ethyl esters A are all in the ethyl ester form, whereas omega-3-carboxylic acids are in the free fatty acid form.<xref ref-type="bibr" rid="article-26163.r6">[6]</xref>&#x000a0;</p>
        <p>
<bold>Adult Dosage, Dosage Forms, and Strengths</bold>
</p>
        <p>The FDA-approved uses of omega-3 fatty acids for adults (older than 18) with hypertriglyceridemia (&#x02265;500 mg/dL) as an adjunct to diet and exercise.<xref ref-type="bibr" rid="article-26163.r3">[3]</xref><xref ref-type="bibr" rid="article-26163.r4">[4]</xref><xref ref-type="bibr" rid="article-26163.r6">[6]</xref>&#x000a0;Specific dosing is as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>Icosapent ethyl is administered&#x000a0;as capsules with a daily dose of 4 g/d, as&#x000a0;2 2-gram capsules twice daily with meals.</p>
          </list-item>
          <list-item>
            <p>Omega-3-acid ethyl esters are administered as capsules with a daily dose of 4 g/d taken as 4 capsules once&#x000a0;daily with meals or&#x000a0;2 capsules twice&#x000a0;daily with meals.</p>
          </list-item>
          <list-item>
            <p>Omega-3-carboxylic acids are administered as capsules with a daily dose of 2 g/d taken as 2 capsules once&#x000a0;daily or 4 g/d taken as 4 capsules once daily. Clinical trial administration was without regard to meals.</p>
          </list-item>
          <list-item>
            <p>Omega-3-acid ethyl esters A are administered as capsules with a daily dose of 4 g/d taken as 4 capsules once&#x000a0;daily with meals or&#x000a0;2 capsules twice&#x000a0;daily with meals.</p>
          </list-item>
        </list>
        <p>All omega-3 fatty acid supplements should be taken whole without being crushed, chewed, or dissolved in the mouth. If a dose is missed, the patient should take it as soon as they remember and not take a double dose if it is time for their next capsule. Various dietary supplements in different chemical forms are currently available over the counter but have not been FDA-approved; they are not required to show safety and efficacy before marketing the product.<xref ref-type="bibr" rid="article-26163.r3">[3]</xref></p>
        <p>
<bold>Special Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment:&#x000a0;</bold>Dosing in patients with hepatic impairment is undefined.</p>
        <p><bold>Renal impairment:</bold>&#x000a0;Dosing in patients with&#x000a0;renal impairment is undefined.</p>
        <p><bold>Pregnant women:&#x000a0;</bold>No human data exists for&#x000a0;omega-3 fatty acid therapy dosing in patients who are pregnant; fetal harm is not expected based on data from fish oil.</p>
        <p><bold>Breastfeeding women:&#x000a0;</bold>Recommendations during breastfeeding are for 1000 mg of DHA plus EPA.</p>
        <p><bold>Pediatric patients:&#x000a0;</bold>The FDA does not approve omega-3 fatty acid therapy for&#x000a0;patients&#x000a0;younger than 18.</p>
        <p><bold>Older patients:&#x000a0;</bold>No data indicates older patients will experience problems from using&#x000a0;omega-3 fatty acids. Paradoxically, although many purported benefits of&#x000a0;omega-3 fatty acids would help older adults, there is a lack of data focusing on this population of patients.<xref ref-type="bibr" rid="article-26163.r62">[62]</xref></p>
      </sec>
      <sec id="article-26163.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The FDA-approved fatty acid prescriptions (icosapent ethyl, omega-3-acid ethyl esters, omega-3-carboxylic acids, and omega-3-acid ethyl esters A) are generally safe with benign effects such as fishy taste, eructation, dyspepsia, diarrhea, gas, nausea, and arthralgia.<xref ref-type="bibr" rid="article-26163.r4">[4]</xref><xref ref-type="bibr" rid="article-26163.r64">[64]</xref><xref ref-type="bibr" rid="article-26163.r65">[65]</xref>&#x000a0;Researchers noted adverse reactions in clinical trials for each FDA-approved omega-3 fatty acid product.<xref ref-type="bibr" rid="article-26163.r4">[4]</xref><xref ref-type="bibr" rid="article-26163.r3">[3]</xref><xref ref-type="bibr" rid="article-26163.r6">[6]</xref>&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Icosapent ethyl: arthralgia and oropharyngeal pain.</p>
          </list-item>
          <list-item>
            <p>Omega-3-acid ethyl esters: eructation, dyspepsia, taste perversion, constipation, GI disorder, vomiting, increased ALT/AST, pruritus, rash.</p>
          </list-item>
          <list-item>
            <p>Omega-3-carboxylic acids: Diarrhea, nausea, abdominal pain or discomfort, eructation, abdominal distension, constipation, vomiting, fatigue, nasopharyngitis, arthralgia, dysgeusia.</p>
          </list-item>
          <list-item>
            <p>Omega-3-acid ethyl esters A: Eructation, dyspepsia, taste perversion, constipation, GI disorder, vomiting, increased ALT/AST, pruritus, rash.</p>
          </list-item>
        </list>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <p>Clinical trials with omega-3 fatty acids demonstrated prolongation of bleeding time. The prolonged bleeding time reported in these trials&#x000a0;did not exceed normal limits or produce clinically significant bleeding episodes. No clinical trials have been&#x000a0;conducted to thoroughly examine the effect of omega-3 fatty acids and concurrent anticoagulant therapy. Patients taking omega-3 fatty acids concurrently with anticoagulant medications or&#x000a0;other drugs affecting coagulation (eg, anti-platelet agents) require periodic monitoring.</p>
      </sec>
      <sec id="article-26163.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Caution and periodic monitoring are recommended in patients taking antiplatelet and anticoagulant medication due to the ability of omega-3 fatty acids to reduce platelet activity.<xref ref-type="bibr" rid="article-26163.r4">[4]</xref><xref ref-type="bibr" rid="article-26163.r15">[15]</xref>&#x000a0;Additionally, omega-3 fatty acids are not considered allergenic, but the FDA labels state to use with caution in patients allergic to seafood. Omega-3 fatty acid products are contraindicated for those with hypersensitivity to the individual formulation.<xref ref-type="bibr" rid="article-26163.r4">[4]</xref></p>
        <p>EPA and DHA can act as alternative substrates for CYP450 metabolism and are partially metabolized by the CYP450 metabolic pathway. However, significant inhibition of CYP450 enzymes by DHA or EPA has not been observed, and no drug-drug interactions have been established with medications that use the CYP450 metabolic pathway. EPA-exclusive supplements have shown to have no drug-drug interactions with other medications that may use the P450 metabolic pathway, such as omeprazole, warfarin, atorvastatin, and rosiglitazone. DHA has been shown to have no interactions with other statin drugs.</p>
      </sec>
      <sec id="article-26163.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>It is recommended that the healthcare provider monitor the direct low-density lipoprotein (LDL) cholesterol for patients taking the DHA-containing products omega-3-acid ethyl esters, omega-3-acid ethyl esters A, and omega-3-carboxylic acids due to DHA&#x02019;s association with an increase in LDL cholesterol.<xref ref-type="bibr" rid="article-26163.r6">[6]</xref></p>
        <p>In patients with dyslipidemia, icosapent ethyl&#x000a0;is an option&#x000a0;since it has no association with increased LDL cholesterol.<xref ref-type="bibr" rid="article-26163.r3">[3]</xref><xref ref-type="bibr" rid="article-26163.r4">[4]</xref><xref ref-type="bibr" rid="article-26163.r6">[6]</xref>&#x000a0;For patients with hepatic impairment, monitoring of the AST and ALT should also be done.<xref ref-type="bibr" rid="article-26163.r6">[6]</xref>&#x000a0;In patients with paroxysmal or persistent atrial fibrillation, the prescription products containing omega-3-acid ethyl esters and omega-3-acid ethyl esters A are possibly associated with increased recurrences of symptomatic atrial fibrillation or flutter.<xref ref-type="bibr" rid="article-26163.r6">[6]</xref></p>
      </sec>
      <sec id="article-26163.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>EPA and DHA are considered generally safe. The FDA recommends that daily intake not exceed 3 g/d of EPA and DHA combined, with no more than 2 g/d deriving from supplements.</p>
        <p>Caution&#x000a0;is necessary when taking high doses as it may reduce immune function because of inflammatory response changes and cause bleeding problems. EPA and DHA are not carcinogenic or mutagenic in human models, but icosapent ethyl (EPA-only formulation) has shown benign neoplasm growth in murine models.</p>
        <p>The FDA-approved fatty acid prescriptions (icosapent ethyl, omega-3-acid ethyl esters, omega-3-carboxylic acids, and omega-3-acid ethyl esters A) are all pregnancy category C drugs, and it is unknown if the drug can cause fetal harm or can affect reproductive capacity. Conversely, some studies concluded that pregnant mothers should incorporate DHA into their diet via high-DHA-content food or supplements to increase latency and birth weight.<xref ref-type="bibr" rid="article-26163.r66">[66]</xref>&#x000a0;</p>
        <p>Additionally, it is not recommended that nursing mothers take DHA or EPA supplements because they can be highly concentrated (possibly 6&#x000a0;to 14 times serum levels), requiring only 200&#x000a0;to 300 mg DHA intake per day in a nursing mother.<xref ref-type="bibr" rid="article-26163.r67">[67]</xref></p>
        <p>Methyl mercury, a toxic organometallic cation, is found in fish. Individuals who use fish as their primary source of omega-3 fatty acids or pregnant and nursing women should limit their intake to&#x000a0;2 to&#x000a0;4 servings of fish a week or replace fish that are high in methyl mercury, such as swordfish, albacore tuna, dolphinfish, kingfish, and shark and replace with fish that have a lower amount of methyl mercury, such as salmon, herring, sardines, and trout.<xref ref-type="bibr" rid="article-26163.r68">[68]</xref><xref ref-type="bibr" rid="article-26163.r69">[69]</xref><xref ref-type="bibr" rid="article-26163.r70">[70]</xref>&#x000a0;Fortunately, DHA and EPA supplements do not contain methyl mercury.</p>
      </sec>
      <sec id="article-26163.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Proper patient education on dosage and use of the prescription EPA-only icosapent ethyl and DHA/EPA formulations is necessary to ensure that the patient achieves the therapeutic benefits. The responsibility of the interprofessional healthcare team, which includes physicians, nurse practitioners, physician assistants, nursing staff, and pharmacists, is to ensure the patient is aware of the possible adverse effects. This is especially important true for individuals on polypharmacy with multiple comorbidities, like those with hepatic and pancreatic impairment, those taking anticoagulants, and individuals with a possible fish sensitivity. Proper physician education on considerations when prescribing, monitoring, and stopping treatment is also necessary.</p>
        <p>Current FDA guidelines approve DHA and EPA for use in patients with very high triglycerides in conjunction with proper diet and exercise. The patient should be encouraged to eat a balanced diet (low in cholesterol) and regular exercise. Routine monitoring should occur when prescribing icosapent ethyl (EPA only) and DHA/EPA formulation to patients with hypertriglyceridemia to check the level of triglycerides and AST and ALT for hepatic function. Care is also necessary when prescribing EPA and DHA to pregnant and nursing patients because of unknown toxicity to the fetus and infant. Pharmacists and clinicians should also inform the patient that better absorption of EPA and DHA occurs when co-administered with food.&#x000a0;</p>
        <p>The healthcare team should remain knowledgeable of other potential DHA and EPA indications.&#x000a0;Fish oil is also available over the counter; patients may take&#x000a0;supplements even&#x000a0;when&#x000a0;not recommended.&#x000a0;The clinical team can help patients taking over-the-counter EPA and DHA supplements by informing them of foods they could incorporate into their diet if they want to stop them. Furthermore, physicians should inquire about patients' diets to ensure proper DHA and EPA levels and fish high in methyl mercury are avoided.</p>
      </sec>
      <sec id="article-26163.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=26163&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=26163">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/26163/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=26163">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-26163.s11">
        <title>References</title>
        <ref id="article-26163.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shahidi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ambigaipalan</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Omega-3 Polyunsaturated Fatty Acids and Their Health Benefits.</article-title>
            <source>Annu Rev Food Sci Technol</source>
            <year>2018</year>
            <month>Mar</month>
            <day>25</day>
            <volume>9</volume>
            <fpage>345</fpage>
            <page-range>345-381</page-range>
            <pub-id pub-id-type="pmid">29350557</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26163.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Behl</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kotwani</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Omega-3 fatty acids in prevention of diabetic retinopathy.</article-title>
            <source>J Pharm Pharmacol</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>69</volume>
            <issue>8</issue>
            <fpage>946</fpage>
            <page-range>946-954</page-range>
            <pub-id pub-id-type="pmid">28481011</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26163.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fialkow</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Omega-3 Fatty Acid Formulations in Cardiovascular Disease: Dietary Supplements are Not Substitutes for Prescription Products.</article-title>
            <source>Am J Cardiovasc Drugs</source>
            <year>2016</year>
            <month>Aug</month>
            <volume>16</volume>
            <issue>4</issue>
            <fpage>229</fpage>
            <page-range>229-239</page-range>
            <pub-id pub-id-type="pmid">27138439</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26163.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Skulas-Ray</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>PWF</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Brinton</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Kris-Etherton</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Richter</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>Jacobson</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Engler</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Robinson</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Blum</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Rodriguez-Leyva</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>de Ferranti</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Welty</surname>
                <given-names>FK</given-names>
              </name>
              <collab>American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; and Council on Clinical Cardiology</collab>
            </person-group>
            <article-title>Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association.</article-title>
            <source>Circulation</source>
            <year>2019</year>
            <month>Sep</month>
            <day>17</day>
            <volume>140</volume>
            <issue>12</issue>
            <fpage>e673</fpage>
            <page-range>e673-e691</page-range>
            <pub-id pub-id-type="pmid">31422671</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26163.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Jia</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Dietary Supplementation with Anti-Inflammatory Omega-3 Fatty Acids for Cardiovascular Protection: Help or Hoax?</article-title>
            <source>React Oxyg Species (Apex)</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>7</volume>
            <issue>20</issue>
            <fpage>78</fpage>
            <page-range>78-85</page-range>
            <pub-id pub-id-type="pmid">30854465</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26163.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ito</surname>
                <given-names>MK</given-names>
              </name>
            </person-group>
            <article-title>A Comparative Overview of Prescription Omega-3 Fatty Acid Products.</article-title>
            <source>P T</source>
            <year>2015</year>
            <month>Dec</month>
            <volume>40</volume>
            <issue>12</issue>
            <fpage>826</fpage>
            <page-range>826-57</page-range>
            <pub-id pub-id-type="pmid">26681905</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26163.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Choi</surname>
                <given-names>HD</given-names>
              </name>
              <name>
                <surname>Chae</surname>
                <given-names>SM</given-names>
              </name>
            </person-group>
            <article-title>Comparison of efficacy and safety of combination therapy with statins and omega-3 fatty acids versus statin monotherapy in patients with dyslipidemia: A systematic review and meta-analysis.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>97</volume>
            <issue>50</issue>
            <fpage>e13593</fpage>
            <pub-id pub-id-type="pmid">30558030</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26163.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Jeon</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Won</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Min</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Byun</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Ahn</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hong</surname>
                <given-names>YJ</given-names>
              </name>
              <name>
                <surname>Sung</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hur</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Hong</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>IB</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>IJ</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>HS</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and Safety of Adding Omega-3 Fatty Acids in Statin-treated Patients with Residual Hypertriglyceridemia: ROMANTIC (Rosuvastatin-OMAcor iN residual hyperTrIglyCeridemia), a Randomized, Double-blind, and Placebo-controlled Trial.</article-title>
            <source>Clin Ther</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>40</volume>
            <issue>1</issue>
            <fpage>83</fpage>
            <page-range>83-94</page-range>
            <pub-id pub-id-type="pmid">29223557</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26163.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barter</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ginsberg</surname>
                <given-names>HN</given-names>
              </name>
            </person-group>
            <article-title>Effectiveness of combined statin plus omega-3 fatty acid therapy for mixed dyslipidemia.</article-title>
            <source>Am J Cardiol</source>
            <year>2008</year>
            <month>Oct</month>
            <day>15</day>
            <volume>102</volume>
            <issue>8</issue>
            <fpage>1040</fpage>
            <page-range>1040-5</page-range>
            <pub-id pub-id-type="pmid">18929706</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26163.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gutstein</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Copple</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Cardiovascular disease and omega-3s: Prescription products and fish oil dietary supplements are not the same.</article-title>
            <source>J Am Assoc Nurse Pract</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>29</volume>
            <issue>12</issue>
            <fpage>791</fpage>
            <page-range>791-801</page-range>
            <pub-id pub-id-type="pmid">29280361</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26163.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weintraub</surname>
                <given-names>HS</given-names>
              </name>
            </person-group>
            <article-title>Overview of prescription omega-3 fatty acid products for hypertriglyceridemia.</article-title>
            <source>Postgrad Med</source>
            <year>2014</year>
            <month>Nov</month>
            <volume>126</volume>
            <issue>7</issue>
            <fpage>7</fpage>
            <page-range>7-18</page-range>
            <pub-id pub-id-type="pmid">25387209</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26163.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Calder</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Deckelbaum</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Editorial: Omega-3 fatty acids and cardiovascular outcomes: an update.</article-title>
            <source>Curr Opin Clin Nutr Metab Care</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>22</volume>
            <issue>2</issue>
            <fpage>97</fpage>
            <page-range>97-102</page-range>
            <pub-id pub-id-type="pmid">30585800</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26163.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Endo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Arita</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Cardioprotective mechanism of omega-3 polyunsaturated fatty acids.</article-title>
            <source>J Cardiol</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>67</volume>
            <issue>1</issue>
            <fpage>22</fpage>
            <page-range>22-7</page-range>
            <pub-id pub-id-type="pmid">26359712</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26163.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Simopoulos</surname>
                <given-names>AP</given-names>
              </name>
            </person-group>
            <article-title>The importance of the ratio of omega-6/omega-3 essential fatty acids.</article-title>
            <source>Biomed Pharmacother</source>
            <year>2002</year>
            <month>Oct</month>
            <volume>56</volume>
            <issue>8</issue>
            <fpage>365</fpage>
            <page-range>365-79</page-range>
            <pub-id pub-id-type="pmid">12442909</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26163.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nabavi</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Bilotto</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Russo</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Orhan</surname>
                <given-names>IE</given-names>
              </name>
              <name>
                <surname>Habtemariam</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Daglia</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Devi</surname>
                <given-names>KP</given-names>
              </name>
              <name>
                <surname>Loizzo</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Tundis</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Nabavi</surname>
                <given-names>SM</given-names>
              </name>
            </person-group>
            <article-title>Omega-3 polyunsaturated fatty acids and cancer: lessons learned from clinical trials.</article-title>
            <source>Cancer Metastasis Rev</source>
            <year>2015</year>
            <month>Sep</month>
            <volume>34</volume>
            <issue>3</issue>
            <fpage>359</fpage>
            <page-range>359-80</page-range>
            <pub-id pub-id-type="pmid">26227583</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26163.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jing</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Omega-3 polyunsaturated fatty acids and cancer.</article-title>
            <source>Anticancer Agents Med Chem</source>
            <year>2013</year>
            <month>Oct</month>
            <volume>13</volume>
            <issue>8</issue>
            <fpage>1162</fpage>
            <page-range>1162-77</page-range>
            <pub-id pub-id-type="pmid">23919748</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26163.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Costantini</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Molinari</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Farinon</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Merendino</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Impact of Omega-3 Fatty Acids on the Gut Microbiota.</article-title>
            <source>Int J Mol Sci</source>
            <year>2017</year>
            <month>Dec</month>
            <day>07</day>
            <volume>18</volume>
            <issue>12</issue>
            <pub-id pub-id-type="pmid">29215589</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26163.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sakamoto</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Saotome</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Iguchi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Maekawa</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Marine-Derived Omega-3 Polyunsaturated Fatty Acids and Heart Failure: Current Understanding for Basic to Clinical Relevance.</article-title>
            <source>Int J Mol Sci</source>
            <year>2019</year>
            <month>Aug</month>
            <day>18</day>
            <volume>20</volume>
            <issue>16</issue>
            <pub-id pub-id-type="pmid">31426560</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26163.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>NaPier</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Kanim</surname>
                <given-names>LEA</given-names>
              </name>
              <name>
                <surname>Arabi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Salehi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sears</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Perry</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sheyn</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bae</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>Glaeser</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Omega-3 Fatty Acid Supplementation Reduces Intervertebral Disc Degeneration.</article-title>
            <source>Med Sci Monit</source>
            <year>2019</year>
            <month>Dec</month>
            <day>14</day>
            <volume>25</volume>
            <fpage>9531</fpage>
            <page-range>9531-9537</page-range>
            <pub-id pub-id-type="pmid">31836696</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26163.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chang</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Su</surname>
                <given-names>KP</given-names>
              </name>
              <name>
                <surname>Mondelli</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Pariante</surname>
                <given-names>CM</given-names>
              </name>
            </person-group>
            <article-title>Omega-3 Polyunsaturated Fatty Acids in Youths with Attention Deficit Hyperactivity Disorder: a Systematic Review and Meta-Analysis of Clinical Trials and Biological Studies.</article-title>
            <source>Neuropsychopharmacology</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>43</volume>
            <issue>3</issue>
            <fpage>534</fpage>
            <page-range>534-545</page-range>
            <pub-id pub-id-type="pmid">28741625</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26163.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bozzatello</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Brignolo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>De Grandi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bellino</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Supplementation with Omega-3 Fatty Acids in Psychiatric Disorders: A Review of Literature Data.</article-title>
            <source>J Clin Med</source>
            <year>2016</year>
            <month>Jul</month>
            <day>27</day>
            <volume>5</volume>
            <issue>8</issue>
            <pub-id pub-id-type="pmid">27472373</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26163.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hsu</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Tung</surname>
                <given-names>CY</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>HE</given-names>
              </name>
            </person-group>
            <article-title>Omega-3 polyunsaturated fatty acid supplementation in prevention and treatment of maternal depression: Putative mechanism and recommendation.</article-title>
            <source>J Affect Disord</source>
            <year>2018</year>
            <month>Oct</month>
            <day>01</day>
            <volume>238</volume>
            <fpage>47</fpage>
            <page-range>47-61</page-range>
            <pub-id pub-id-type="pmid">29860183</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26163.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mohammady</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Janani</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Jahanfar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mousavi</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>Effect of omega-3 supplements on vasomotor symptoms in menopausal women: A systematic review and meta-analysis.</article-title>
            <source>Eur J Obstet Gynecol Reprod Biol</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>228</volume>
            <fpage>295</fpage>
            <page-range>295-302</page-range>
            <pub-id pub-id-type="pmid">30056356</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26163.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brigham</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Woo</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>McCormack</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rice</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Koehler</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Vulcain</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Koch</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kolahdooz</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Bose</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hanson</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Romero</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Diette</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hansel</surname>
                <given-names>NN</given-names>
              </name>
            </person-group>
            <article-title>Omega-3 and Omega-6 Intake Modifies Asthma Severity and Response to Indoor Air Pollution in Children.</article-title>
            <source>Am J Respir Crit Care Med</source>
            <year>2019</year>
            <month>Jun</month>
            <day>15</day>
            <volume>199</volume>
            <issue>12</issue>
            <fpage>1478</fpage>
            <page-range>1478-1486</page-range>
            <pub-id pub-id-type="pmid">30922077</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26163.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kumar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mastana</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Lindley</surname>
                <given-names>MR</given-names>
              </name>
            </person-group>
            <article-title>n-3 Fatty acids and asthma.</article-title>
            <source>Nutr Res Rev</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>29</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-16</page-range>
            <pub-id pub-id-type="pmid">26809946</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26163.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chee</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Fitzsimmons</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Coates</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Bartold</surname>
                <given-names>PM</given-names>
              </name>
            </person-group>
            <article-title>Omega-3 fatty acids as an adjunct for periodontal therapy-a review.</article-title>
            <source>Clin Oral Investig</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>20</volume>
            <issue>5</issue>
            <fpage>879</fpage>
            <page-range>879-94</page-range>
            <pub-id pub-id-type="pmid">26885664</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26163.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bahagat</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Elhady</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Aziz</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Youness</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Zakzok</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>[Omega-6/omega-3 ratio and cognition in children with epilepsy].</article-title>
            <source>An Pediatr (Engl Ed)</source>
            <year>2019</year>
            <month>Aug</month>
            <volume>91</volume>
            <issue>2</issue>
            <fpage>88</fpage>
            <page-range>88-95</page-range>
            <pub-id pub-id-type="pmid">30660389</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26163.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tejada</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Martorell</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cap&#x000f3;</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Tur</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Pons</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sureda</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Omega-3 Fatty Acids in the Management of Epilepsy.</article-title>
            <source>Curr Top Med Chem</source>
            <year>2016</year>
            <volume>16</volume>
            <issue>17</issue>
            <fpage>1897</fpage>
            <page-range>1897-905</page-range>
            <pub-id pub-id-type="pmid">26845549</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26163.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rosenberg</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Omega-3 Fatty Acid Intake Lowers Risk of Diabetic Retinopathy.</article-title>
            <source>Am J Nurs</source>
            <year>2017</year>
            <month>Jan</month>
            <volume>117</volume>
            <issue>1</issue>
            <fpage>60</fpage>
            <page-range>60-61</page-range>
            <pub-id pub-id-type="pmid">28030412</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26163.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>de la Rosa Oliva</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Meneses Garc&#x000ed;a</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ruiz Calzada</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Astudillo de la Vega</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bargall&#x000f3; Rocha</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lara-Medina</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Alvarado Miranda</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Matus-Santos</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Flores-D&#x000ed;az</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>O&#x000f1;ate-Acu&#x000f1;a</surname>
                <given-names>LF</given-names>
              </name>
              <name>
                <surname>Guti&#x000e9;rrez-Salme&#x000e1;n</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ruiz Garc&#x000ed;a</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ibarra</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Effects of omega-3 fatty acids supplementation on neoadjuvant chemotherapy-induced toxicity in patients with locally advanced breast cancer: a randomized, controlled, double-blinded clinical trial.</article-title>
            <source>Nutr Hosp</source>
            <year>2019</year>
            <month>Aug</month>
            <day>26</day>
            <volume>36</volume>
            <issue>4</issue>
            <fpage>769</fpage>
            <page-range>769-776</page-range>
            <pub-id pub-id-type="pmid">31192682</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26163.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bahmanyar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Higgins</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Goldgaber</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lewis</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Morrison</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Shankar</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Gajdusek</surname>
                <given-names>DC</given-names>
              </name>
            </person-group>
            <article-title>Localization of amyloid beta protein messenger RNA in brains from patients with Alzheimer's disease.</article-title>
            <source>Science</source>
            <year>1987</year>
            <month>Jul</month>
            <day>03</day>
            <volume>237</volume>
            <issue>4810</issue>
            <fpage>77</fpage>
            <page-range>77-80</page-range>
            <pub-id pub-id-type="pmid">3299701</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26163.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Behboudi-Gandevani</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hariri</surname>
                <given-names>FZ</given-names>
              </name>
              <name>
                <surname>Moghaddam-Banaem</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>The effect of omega 3 fatty acid supplementation on premenstrual syndrome and health-related quality of life: a randomized clinical trial.</article-title>
            <source>J Psychosom Obstet Gynaecol</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>39</volume>
            <issue>4</issue>
            <fpage>266</fpage>
            <page-range>266-272</page-range>
            <pub-id pub-id-type="pmid">28707491</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26163.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Spooner</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Jump</surname>
                <given-names>DB</given-names>
              </name>
            </person-group>
            <article-title>Omega-3 fatty acids and nonalcoholic fatty liver disease in adults and children: where do we stand?</article-title>
            <source>Curr Opin Clin Nutr Metab Care</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>22</volume>
            <issue>2</issue>
            <fpage>103</fpage>
            <page-range>103-110</page-range>
            <pub-id pub-id-type="pmid">30601174</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26163.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Backes</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Anzalone</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hilleman</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Catini</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>The clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemia.</article-title>
            <source>Lipids Health Dis</source>
            <year>2016</year>
            <month>Jul</month>
            <day>22</day>
            <volume>15</volume>
            <issue>1</issue>
            <fpage>118</fpage>
            <pub-id pub-id-type="pmid">27444154</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26163.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Noreen</surname>
                <given-names>EE</given-names>
              </name>
              <name>
                <surname>Sass</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Crowe</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Pabon</surname>
                <given-names>VA</given-names>
              </name>
              <name>
                <surname>Brandauer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Averill</surname>
                <given-names>LK</given-names>
              </name>
            </person-group>
            <article-title>Effects of supplemental fish oil on resting metabolic rate, body composition, and salivary cortisol in healthy adults.</article-title>
            <source>J Int Soc Sports Nutr</source>
            <year>2010</year>
            <month>Oct</month>
            <day>08</day>
            <volume>7</volume>
            <fpage>31</fpage>
            <pub-id pub-id-type="pmid">20932294</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26163.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bays</surname>
                <given-names>HE</given-names>
              </name>
              <name>
                <surname>Tighe</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Sadovsky</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Davidson</surname>
                <given-names>MH</given-names>
              </name>
            </person-group>
            <article-title>Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications.</article-title>
            <source>Expert Rev Cardiovasc Ther</source>
            <year>2008</year>
            <month>Mar</month>
            <volume>6</volume>
            <issue>3</issue>
            <fpage>391</fpage>
            <page-range>391-409</page-range>
            <pub-id pub-id-type="pmid">18327998</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26163.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Le Jossic-Corcos</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gonthier</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zaghini</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Logette</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Shechter</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Bournot</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Hepatic farnesyl diphosphate synthase expression is suppressed by polyunsaturated fatty acids.</article-title>
            <source>Biochem J</source>
            <year>2005</year>
            <month>Feb</month>
            <day>01</day>
            <volume>385</volume>
            <issue>Pt 3</issue>
            <fpage>787</fpage>
            <page-range>787-94</page-range>
            <pub-id pub-id-type="pmid">15473864</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26163.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Horton</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Bashmakov</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Shimomura</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Shimano</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Regulation of sterol regulatory element binding proteins in livers of fasted and refed mice.</article-title>
            <source>Proc Natl Acad Sci U S A</source>
            <year>1998</year>
            <month>May</month>
            <day>26</day>
            <volume>95</volume>
            <issue>11</issue>
            <fpage>5987</fpage>
            <page-range>5987-92</page-range>
            <pub-id pub-id-type="pmid">9600904</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26163.r39">
          <label>39</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Pirahanchi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Anoruo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <chapter-title>Biochemistry, Lipoprotein Lipase</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>30</day>
            <pub-id pub-id-type="pmid">30725725</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26163.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>He</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>OuYang</surname>
                <given-names>XP</given-names>
              </name>
              <name>
                <surname>Liang</surname>
                <given-names>YQ</given-names>
              </name>
              <name>
                <surname>Zou</surname>
                <given-names>JQ</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>QQ</given-names>
              </name>
              <name>
                <surname>Liao</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zheng</surname>
                <given-names>XL</given-names>
              </name>
            </person-group>
            <article-title>Lipoprotein lipase: Biosynthesis, regulatory factors, and its role in atherosclerosis and other diseases.</article-title>
            <source>Clin Chim Acta</source>
            <year>2018</year>
            <month>May</month>
            <volume>480</volume>
            <fpage>126</fpage>
            <page-range>126-137</page-range>
            <pub-id pub-id-type="pmid">29453968</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26163.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mead</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Irvine</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Ramji</surname>
                <given-names>DP</given-names>
              </name>
            </person-group>
            <article-title>Lipoprotein lipase: structure, function, regulation, and role in disease.</article-title>
            <source>J Mol Med (Berl)</source>
            <year>2002</year>
            <month>Dec</month>
            <volume>80</volume>
            <issue>12</issue>
            <fpage>753</fpage>
            <page-range>753-69</page-range>
            <pub-id pub-id-type="pmid">12483461</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26163.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Park</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>WS</given-names>
              </name>
            </person-group>
            <article-title>Omega-3 fatty acid supplementation accelerates chylomicron triglyceride clearance.</article-title>
            <source>J Lipid Res</source>
            <year>2003</year>
            <month>Mar</month>
            <volume>44</volume>
            <issue>3</issue>
            <fpage>455</fpage>
            <page-range>455-63</page-range>
            <pub-id pub-id-type="pmid">12562865</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26163.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Logan</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Spriet</surname>
                <given-names>LL</given-names>
              </name>
            </person-group>
            <article-title>Omega-3 Fatty Acid Supplementation for 12 Weeks Increases Resting and Exercise Metabolic Rate in Healthy Community-Dwelling Older Females.</article-title>
            <source>PLoS One</source>
            <year>2015</year>
            <volume>10</volume>
            <issue>12</issue>
            <fpage>e0144828</fpage>
            <pub-id pub-id-type="pmid">26679702</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26163.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Couet</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Delarue</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ritz</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Antoine</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Lamisse</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Effect of dietary fish oil on body fat mass and basal fat oxidation in healthy adults.</article-title>
            <source>Int J Obes Relat Metab Disord</source>
            <year>1997</year>
            <month>Aug</month>
            <volume>21</volume>
            <issue>8</issue>
            <fpage>637</fpage>
            <page-range>637-43</page-range>
            <pub-id pub-id-type="pmid">15481762</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26163.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kopecky</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rossmeisl</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Flachs</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kuda</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Brauner</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Jilkova</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Stankova</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Tvrzicka</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bryhn</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>n-3 PUFA: bioavailability and modulation of adipose tissue function.</article-title>
            <source>Proc Nutr Soc</source>
            <year>2009</year>
            <month>Nov</month>
            <volume>68</volume>
            <issue>4</issue>
            <fpage>361</fpage>
            <page-range>361-9</page-range>
            <pub-id pub-id-type="pmid">19698199</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26163.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Seo</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Blaner</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Deckelbaum</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Omega-3 fatty acids: molecular approaches to optimal biological outcomes.</article-title>
            <source>Curr Opin Lipidol</source>
            <year>2005</year>
            <month>Feb</month>
            <volume>16</volume>
            <issue>1</issue>
            <fpage>11</fpage>
            <page-range>11-8</page-range>
            <pub-id pub-id-type="pmid">15650558</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26163.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kota</surname>
                <given-names>BP</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Roufogalis</surname>
                <given-names>BD</given-names>
              </name>
            </person-group>
            <article-title>An overview on biological mechanisms of PPARs.</article-title>
            <source>Pharmacol Res</source>
            <year>2005</year>
            <month>Feb</month>
            <volume>51</volume>
            <issue>2</issue>
            <fpage>85</fpage>
            <page-range>85-94</page-range>
            <pub-id pub-id-type="pmid">15629253</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26163.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Calder</surname>
                <given-names>PC</given-names>
              </name>
            </person-group>
            <article-title>Omega-3 fatty acids and inflammatory processes: from molecules to man.</article-title>
            <source>Biochem Soc Trans</source>
            <year>2017</year>
            <month>Oct</month>
            <day>15</day>
            <volume>45</volume>
            <issue>5</issue>
            <fpage>1105</fpage>
            <page-range>1105-1115</page-range>
            <pub-id pub-id-type="pmid">28900017</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26163.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Calder</surname>
                <given-names>PC</given-names>
              </name>
            </person-group>
            <article-title>Omega-3 polyunsaturated fatty acids and inflammatory processes: nutrition or pharmacology?</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>2013</year>
            <month>Mar</month>
            <volume>75</volume>
            <issue>3</issue>
            <fpage>645</fpage>
            <page-range>645-62</page-range>
            <pub-id pub-id-type="pmid">22765297</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26163.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ishihara</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Yoshida</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Arita</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Omega-3 fatty acid-derived mediators that control inflammation and tissue homeostasis.</article-title>
            <source>Int Immunol</source>
            <year>2019</year>
            <month>Aug</month>
            <day>23</day>
            <volume>31</volume>
            <issue>9</issue>
            <fpage>559</fpage>
            <page-range>559-567</page-range>
            <pub-id pub-id-type="pmid">30772915</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26163.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Svensson</surname>
                <given-names>RU</given-names>
              </name>
              <name>
                <surname>Parker</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Eichner</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Kolar</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Brun</surname>
                <given-names>SN</given-names>
              </name>
              <name>
                <surname>Lombardo</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Van Nostrand</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Hutchins</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vera</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gerken</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Greenwood</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bhat</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Harriman</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Westlin</surname>
                <given-names>WF</given-names>
              </name>
              <name>
                <surname>Harwood</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Saghatelian</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kapeller</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Metallo</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Shaw</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Inhibition of acetyl-CoA carboxylase suppresses fatty acid synthesis and tumor growth of non-small-cell lung cancer in preclinical models.</article-title>
            <source>Nat Med</source>
            <year>2016</year>
            <month>Oct</month>
            <volume>22</volume>
            <issue>10</issue>
            <fpage>1108</fpage>
            <page-range>1108-1119</page-range>
            <pub-id pub-id-type="pmid">27643638</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26163.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chew</surname>
                <given-names>EY</given-names>
              </name>
              <name>
                <surname>Clemons</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Agr&#x000f3;n</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Launer</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Grodstein</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Bernstein</surname>
                <given-names>PS</given-names>
              </name>
              <collab>Age-Related Eye Disease Study 2 (AREDS2) Research Group</collab>
            </person-group>
            <article-title>Effect of Omega-3 Fatty Acids, Lutein/Zeaxanthin, or Other Nutrient Supplementation on Cognitive Function: The AREDS2 Randomized Clinical Trial.</article-title>
            <source>JAMA</source>
            <year>2015</year>
            <month>Aug</month>
            <day>25</day>
            <volume>314</volume>
            <issue>8</issue>
            <fpage>791</fpage>
            <page-range>791-801</page-range>
            <pub-id pub-id-type="pmid">26305649</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26163.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sydenham</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Dangour</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>WS</given-names>
              </name>
            </person-group>
            <article-title>Omega 3 fatty acid for the prevention of cognitive decline and dementia.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2012</year>
            <month>Jun</month>
            <day>13</day>
            <issue>6</issue>
            <fpage>CD005379</fpage>
            <pub-id pub-id-type="pmid">22696350</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26163.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tully</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Roche</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Doyle</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Fallon</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bruce</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Lawlor</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Coakley</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gibney</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Low serum cholesteryl ester-docosahexaenoic acid levels in Alzheimer's disease: a case-control study.</article-title>
            <source>Br J Nutr</source>
            <year>2003</year>
            <month>Apr</month>
            <volume>89</volume>
            <issue>4</issue>
            <fpage>483</fpage>
            <page-range>483-9</page-range>
            <pub-id pub-id-type="pmid">12654166</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26163.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>SanGiovanni</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Chew</surname>
                <given-names>EY</given-names>
              </name>
            </person-group>
            <article-title>The role of omega-3 long-chain polyunsaturated fatty acids in health and disease of the retina.</article-title>
            <source>Prog Retin Eye Res</source>
            <year>2005</year>
            <month>Jan</month>
            <volume>24</volume>
            <issue>1</issue>
            <fpage>87</fpage>
            <page-range>87-138</page-range>
            <pub-id pub-id-type="pmid">15555528</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26163.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nodari</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Metra</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Milesi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Manerba</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cesana</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Gheorghiade</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dei Cas</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>The role of n-3 PUFAs in preventing the arrhythmic risk in patients with idiopathic dilated cardiomyopathy.</article-title>
            <source>Cardiovasc Drugs Ther</source>
            <year>2009</year>
            <month>Feb</month>
            <volume>23</volume>
            <issue>1</issue>
            <fpage>5</fpage>
            <page-range>5-15</page-range>
            <pub-id pub-id-type="pmid">18982439</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26163.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Haglund</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Mehta</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Saldeen</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Effects of fish oil on some parameters of fibrinolysis and lipoprotein(a) in healthy subjects.</article-title>
            <source>Am J Cardiol</source>
            <year>1994</year>
            <month>Jul</month>
            <day>15</day>
            <volume>74</volume>
            <issue>2</issue>
            <fpage>189</fpage>
            <page-range>189-92</page-range>
            <pub-id pub-id-type="pmid">8023790</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26163.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schuchardt</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Hahn</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Bioavailability of long-chain omega-3 fatty acids.</article-title>
            <source>Prostaglandins Leukot Essent Fatty Acids</source>
            <year>2013</year>
            <month>Jul</month>
            <volume>89</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-8</page-range>
            <pub-id pub-id-type="pmid">23676322</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26163.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cholewski</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tomczykowa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tomczyk</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>A Comprehensive Review of Chemistry, Sources and Bioavailability of Omega-3 Fatty Acids.</article-title>
            <source>Nutrients</source>
            <year>2018</year>
            <month>Nov</month>
            <day>04</day>
            <volume>10</volume>
            <issue>11</issue>
            <pub-id pub-id-type="pmid">30400360</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26163.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arnold</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Konkel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fischer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Schunck</surname>
                <given-names>WH</given-names>
              </name>
            </person-group>
            <article-title>Cytochrome P450-dependent metabolism of omega-6 and omega-3 long-chain polyunsaturated fatty acids.</article-title>
            <source>Pharmacol Rep</source>
            <year>2010</year>
            <season>May-Jun</season>
            <volume>62</volume>
            <issue>3</issue>
            <fpage>536</fpage>
            <page-range>536-47</page-range>
            <pub-id pub-id-type="pmid">20631419</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26163.r61">
          <label>61</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pawlosky</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Hibbeln</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Salem</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Compartmental analyses of plasma n-3 essential fatty acids among male and female smokers and nonsmokers.</article-title>
            <source>J Lipid Res</source>
            <year>2007</year>
            <month>Apr</month>
            <volume>48</volume>
            <issue>4</issue>
            <fpage>935</fpage>
            <page-range>935-43</page-range>
            <pub-id pub-id-type="pmid">17234605</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26163.r62">
          <label>62</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pawlosky</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Hibbeln</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Novotny</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Salem</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Physiological compartmental analysis of alpha-linolenic acid metabolism in adult humans.</article-title>
            <source>J Lipid Res</source>
            <year>2001</year>
            <month>Aug</month>
            <volume>42</volume>
            <issue>8</issue>
            <fpage>1257</fpage>
            <page-range>1257-65</page-range>
            <pub-id pub-id-type="pmid">11483627</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26163.r63">
          <label>63</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Anderson</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>DW</given-names>
              </name>
            </person-group>
            <article-title>Are all n-3 polyunsaturated fatty acids created equal?</article-title>
            <source>Lipids Health Dis</source>
            <year>2009</year>
            <month>Aug</month>
            <day>10</day>
            <volume>8</volume>
            <fpage>33</fpage>
            <pub-id pub-id-type="pmid">19664246</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26163.r64">
          <label>64</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brinton</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Mason</surname>
                <given-names>RP</given-names>
              </name>
            </person-group>
            <article-title>Prescription omega-3 fatty acid products containing highly purified eicosapentaenoic acid (EPA).</article-title>
            <source>Lipids Health Dis</source>
            <year>2017</year>
            <month>Jan</month>
            <day>31</day>
            <volume>16</volume>
            <issue>1</issue>
            <fpage>23</fpage>
            <pub-id pub-id-type="pmid">28137294</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26163.r65">
          <label>65</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fabian</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Kimler</surname>
                <given-names>BF</given-names>
              </name>
              <name>
                <surname>Hursting</surname>
                <given-names>SD</given-names>
              </name>
            </person-group>
            <article-title>Omega-3 fatty acids for breast cancer prevention and survivorship.</article-title>
            <source>Breast Cancer Res</source>
            <year>2015</year>
            <month>May</month>
            <day>04</day>
            <volume>17</volume>
            <issue>1</issue>
            <fpage>62</fpage>
            <pub-id pub-id-type="pmid">25936773</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26163.r66">
          <label>66</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saccone</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Berghella</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Omega-3 long chain polyunsaturated fatty acids to prevent preterm birth: a systematic review and meta-analysis.</article-title>
            <source>Obstet Gynecol</source>
            <year>2015</year>
            <month>Mar</month>
            <volume>125</volume>
            <issue>3</issue>
            <fpage>663</fpage>
            <page-range>663-672</page-range>
            <pub-id pub-id-type="pmid">25730231</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26163.r67">
          <label>67</label>
          <element-citation publication-type="journal">
            <collab>Section on Breastfeeding</collab>
            <article-title>Breastfeeding and the use of human milk.</article-title>
            <source>Pediatrics</source>
            <year>2012</year>
            <month>Mar</month>
            <volume>129</volume>
            <issue>3</issue>
            <fpage>e827</fpage>
            <page-range>e827-41</page-range>
            <pub-id pub-id-type="pmid">22371471</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26163.r68">
          <label>68</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zamora-Arellano</surname>
                <given-names>NY</given-names>
              </name>
              <name>
                <surname>Betancourt-Lozano</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ilizaliturri-Hern&#x000e1;ndez</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Garc&#x000ed;a-Hern&#x000e1;ndez</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jara-Marini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ch&#x000e1;vez-S&#x000e1;nchez</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ruelas-Inzunza</surname>
                <given-names>JR</given-names>
              </name>
            </person-group>
            <article-title>Mercury Levels and Risk Implications Through Fish Consumption on the Sinaloa Coasts (Gulf of California, Northwest Mexico).</article-title>
            <source>Risk Anal</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>38</volume>
            <issue>12</issue>
            <fpage>2646</fpage>
            <page-range>2646-2658</page-range>
            <pub-id pub-id-type="pmid">30229961</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26163.r69">
          <label>69</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Garc&#x000ed;a-Hern&#x000e1;ndez</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ortega-V&#x000e9;lez</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Contreras-Paniagua</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Aguilera-M&#x000e1;rquez</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Leyva-Garc&#x000ed;a</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Torre</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Mercury concentrations in seafood and the associated risk in women with high fish consumption from coastal villages of Sonora, Mexico.</article-title>
            <source>Food Chem Toxicol</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>120</volume>
            <fpage>367</fpage>
            <page-range>367-377</page-range>
            <pub-id pub-id-type="pmid">30026089</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26163.r70">
          <label>70</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mozaffarian</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Rimm</surname>
                <given-names>EB</given-names>
              </name>
            </person-group>
            <article-title>Fish intake, contaminants, and human health: evaluating the risks and the benefits.</article-title>
            <source>JAMA</source>
            <year>2006</year>
            <month>Oct</month>
            <day>18</day>
            <volume>296</volume>
            <issue>15</issue>
            <fpage>1885</fpage>
            <page-range>1885-99</page-range>
            <pub-id pub-id-type="pmid">17047219</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
